Cypherpunk Technologies' (CYPH) "Overweight" Rating Reiterated at Cantor Fitzgerald

Key Points

• Cantor Fitzgerald reaffirmed its “overweight” rating on Cypherpunk Technologies and maintained a $1.60 price target, slightly below the stock’s $1.63 opening price.
• Analyst sentiment is mixed: one analyst rates the shares Buy and another Sell, resulting in a consensus “Hold” rating with an average target price of $1.60.
• CYPH reported quarterly EPS of $0.18, while institutional investors own 30.46% of the company; Acadian Asset Management increased its stake by 470.4% during the first quarter.

Cypherpunk Technologies (NASDAQ:CYPH - Get Free Report)'s stock had its "overweight" rating reaffirmed by equities research analysts at Cantor Fitzgerald in a note issued to investors on Thursday,Benzinga reports. They currently have a $1.60 price target on the stock. Cantor Fitzgerald's price target indicates a potential downside of 1.84% from the company's current price.

Several other research firms have also weighed in on CYPH. Weiss Ratings upgraded shares of Cypherpunk Technologies from a "sell (e+)" rating to a "sell (d-)" rating in a report on Monday, August 17th. Wall Street Zen raised shares of Cypherpunk Technologies from a "sell" rating to a "hold" rating in a report on Saturday, July 4th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $1.60.

Cypherpunk Technologies Stock Performance

Shares of CYPH stock opened at $1.63 on Thursday. Cypherpunk Technologies has a 52 week low of $0.27 and a 52 week high of $3.70. The stock has a market capitalization of $175.66 million, a PE ratio of 2.91 and a beta of 0.09. The stock's fifty day moving average is $0.77 and its 200-day moving average is $0.81.

Cypherpunk Technologies (NASDAQ:CYPH - Get Free Report) last released its earnings results on Wednesday, August 12th. The company reported $0.18 EPS for the quarter.

Institutional Investors Weigh In On Cypherpunk Technologies

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CYPH. Acadian Asset Management LLC boosted its stake in shares of Cypherpunk Technologies by 470.4% during the 1st quarter. Acadian Asset Management LLC now owns 1,280,531 shares of the company's stock worth $389,000 after buying an additional 1,056,047 shares during the last quarter. Sequoia Financial Advisors LLC acquired a new stake in shares of Cypherpunk Technologies in the fourth quarter valued at about $56,000. HighTower Advisors LLC bought a new stake in Cypherpunk Technologies during the fourth quarter worth about $59,000. Simplify Asset Management Inc. bought a new stake in Cypherpunk Technologies during the fourth quarter worth about $2,172,000. Finally, Texas Capital Bank Wealth Management Services Inc acquired a new position in Cypherpunk Technologies during the fourth quarter valued at approximately $121,000. 30.46% of the stock is currently owned by institutional investors and hedge funds.

Cypherpunk Technologies Company Profile

Cypherpunk Technologies Inc, previously known as Leap Therapeutics, Inc, is a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The company’s research platform centers on modulating the tumor microenvironment to enhance anti-tumor immune responses. Cypherpunk’s proprietary pipeline includes DKN-01, a monoclonal antibody designed to neutralize Dickkopf-1 (DKK1), a protein implicated in tumor growth and immune evasion.

DKN-01 is being evaluated both as a monotherapy and in combination with checkpoint inhibitors such as pembrolizumab across multiple solid tumor indications, including gastroesophageal, pancreatic and other advanced malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source